SPDR S&P Biotech ETF
703 hedge funds and large institutions have $6.3B invested in SPDR S&P Biotech ETF in 2022 Q2 according to their latest regulatory filings, with 121 funds opening new positions, 249 increasing their positions, 196 reducing their positions, and 110 closing their positions.
New
Increased
Maintained
Reduced
Closed
more funds holding in top 10
Funds holding in top 10: →
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more first-time investments, than exits
New positions opened: | Existing positions closed:
more call options, than puts
Call options by funds: $ | Put options by funds: $
0% more funds holding
Funds holding: 700 → 703 (+3)
7.36% less ownership
Funds ownership: 97.76% → 90.4% (-7.4%)
11% less capital invested
Capital invested by funds: $7.06B → $6.3B (-$760M)
Holders
703
Holding in Top 10
32
Calls
$1.8B
Puts
$1.78B
Top Buyers
| 1 | +$239M | |
| 2 | +$146M | |
| 3 | +$107M | |
| 4 |
HIIFS
Harel Insurance Investments & Financial Services
Ramat Gan,
Israel
|
+$85.4M |
| 5 |
Citigroup
New York
|
+$75.1M |
Top Sellers
| 1 | -$189M | |
| 2 | -$160M | |
| 3 | -$73.3M | |
| 4 |
Northwestern Mutual Wealth Management
Milwaukee,
Wisconsin
|
-$51.8M |
| 5 |
BNP Paribas Financial Markets
Paris,
France
|
-$45.3M |